Microscale Bioreactors for On-Demand Protein Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bioprocessing systems for producing therapeutic proteins are complex, time-consuming, and unsuitable for rapid production or personalized therapeutics, particularly for infectious diseases and rare disorders.
Innovation Solution
An integrated and compact bioprocessing system that includes a production module for producing proteins from cells extracted from blood and a purification module for purifying the proteins, enabling on-demand production and delivery of therapeutic proteins directly to patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If large scale centralized manufacturing facilities are used, then manufacturing precision and reliability are improved, but device complexity and time consumption increase significantly
Solution Approach 1:
The patent divides the centralized manufacturing process into distributed microscale bioreactors that can operate independently. Each bioreactor is a self-contained unit capable of producing therapeutic proteins, eliminating the need for complex centralized facilities while maintaining manufacturing precision through standardized modular designs.
Solution Approach 2:
The patent extracts the core protein production function from the complex centralized manufacturing facility, creating standalone microscale bioreactors. This extraction removes unnecessary complexity while preserving the essential capability of producing high-quality therapeutic proteins through controlled cellular cultivation.
2Manufacturing precision
If large scale centralized manufacturing is used, then manufacturing precision is improved, but production time and loss of time increase
Solution Approach 1:
The patent implements preliminary action by maintaining ready-to-use cell banks that can be rapidly deployed into microscale bioreactors when production is needed. This pre-positioning of biological materials eliminates lengthy preparation phases and enables immediate production, drastically reducing the time from cell bank to final delivery while maintaining protein quality through controlled cultivation conditions.
Solution Approach 2:
The patent enables continuous production through parallel operation of multiple microscale bioreactors. While one bioreactor is being used, others can be prepared or are already in production, creating a continuous workflow that eliminates idle time and accelerates the overall production timeline without compromising manufacturing precision.
3Device complexity
If cell-free systems are used, then device complexity is reduced, but manufacturing precision and reliability worsen
Solution Approach 1:
The patent applies local quality by providing each microscale bioreactor with site-specific optimization for glycosylation. The system can adjust local cultivation conditions (pH, temperature, nutrients) within each bioreactor to achieve consistent glycosylation profiles, compensating for the simpler device architecture with localized process control that maintains manufacturing precision.
4Productivity
If rapid production is implemented, then productivity is improved, but manufacturing precision may worsen
Solution Approach 1:
The patent implements dynamics by enabling rapid scaling of production through parallel deployment of multiple microscale bioreactors. The system can dynamically adjust the number of active bioreactors based on production demands, achieving high productivity through parallelization rather than speeding up individual processes, thereby maintaining manufacturing precision while increasing overall output capacity.
Data Source
AI summary
A bioprocessing system for protein manufacturing from human blood is provided that is compact, integrated and suited for on-demand production and delivery of therapeutic proteins to patients. The patient's own blood can be used as the source of cell extracts for the production of the therapeutic proteins.